Effects of luteinizing hormone and follicle stimulating hormone on the developmental competence of porcine preantral follicle oocytes grown in vitro

Background There has been controversy over the role of FSH in the regulation of preantral follicle development. LH is a survival and differentiation factor that increases oocyte maturation in FSH-supplemented cultures of mouse preantral follicles. However, little information exists on the action of LH and FSH in the developmental competence of porcine preantral follicle oocytes in vitro. Materials and methods Porcine preantral follicles were cultured for 3 days in the presence or absence of FSH or LH. Oocytes from these follicles were then matured, fertilized in vitro, and embryos were cultured. Estradiol secretion and histological analysis of cultured follicles were also carried out. Results FSH or combined LH and FSH significantly enhanced follicular growth compared to LH alone or the controls. Combined LH and FSH treatment of preantral follicles significantly increased the percentage (59 ± 5%) of oocytes competent to undergo cleavage to the two-cell stage after fertilization. A significant effect was seen on oocyte competence to develop from the two-cell to the blastocyst stage (30 ± 6%) compared to FSH alone treatment (45 ± 7 and 14 ± 5%, respectively). The amount of estradiol on days 2 and 3 of culture was significantly higher in follicles cultured with FSH (48.75 ± 17, 70.5 ± 14 pg/ml) or combined LH and FSH (63.25 ± 16, 72.5 ± 12 pg/ml) than that cultured with the untreated controls (16 ± 10, 5.66 ± 4 pg/ml). Conclusions The results indicated that FSH is essential for the in vitro growth of porcine preantral follicles, estradiol secretion, and for oocytes to acquire competence to resume meiosis and undergo fertilization and embryonic development. LH with FSH treatment of porcine preantral follicles can improve the quality of oocytes by promoting growth and a higher frequency of embryonic development.     

Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing hormone agonist and stimulated with recombinant follicle-stimulating hormone

OBJECTIVE: To assess the value of serum LH measurements in early and late follicular phase as predictors of ovarian response and IVF outcome in patients treated with recombinant FSH with GnRH agonist (GnRH-a) pituitary down-regulation. DESIGN: Retrospective cohort analysis. SETTING: Institutional. PATIENT(S): Women undergoing 157 consecutive IVF cycles suppressed with leuprolide acetate (LA) started in the midluteal phase and stimulated with recombinant FSH. Only women <40 years of age and with a basal cycle day 3 serum FSH 相似文献   

The effect of human cumulus cells on the maturation and developmental potential of immature oocytes in ICSI cycles

Purpose  

To investigate the effect of human cumulus cells on the maturation and developmental potential of immature oocytes in ICSI cycles.     

Danazol stimulates the release of follicle-stimulating hormone and inhibits the release of prolactin in vitro studies on rat pituitary cell cultures

Summary The actions of danazol on the release of gonadotropins and prolactin (PRL) were investigated by using a culture of rat anterior pituitary gland cells. The addition of danazol in the range between 10^–9M and 10^–5M elevated the levels of follicle-stimulating hormone (FSH) in a dose-dependent manner. Danazol at 10^–5M caused a 70% increase in FSH levels over the control. The intracellular contents of FSH was also increased by danazol, suggesting its stimulatory effect on both the synthesis and release of FSH. Danazol had no effect on the release of luteinizing hormone (LH). Danazol diminished the sensitivity of gonadotrophs to luteinizing hormone-releasing hormone (LHRH) in that the LHRH-induced release of both FSH and LH was suppressed. The amount of PRL released into medium was decreased by danazol in a dose-dependent way.     

冻融后小鼠卵母细胞培养时间对ICSI结果的影响及受精失败辅助激活的结果

目的:研究冻存后的小鼠成熟卵母细胞复苏后培养不同时间对ICSI结果的影响,观察Ca2+载体霉素联合嘌呤霉素对ICSI受精失败的卵母细胞补救激活的有效性。方法:采用慢冻-快融程序化冷冻方法冻融小鼠成熟卵母细胞,复苏后卵母细胞分别培养不同时间(1h、2h、3h、4h、5h)后行ICSI,比较其受精和胚胎发育情况。冻融后受精失败的卵母细胞分为两组(A组:辅助激活,B组:不采取辅助激活),另外获取ICSI受精失败的新鲜卵母细胞(C组)采用和A组同样方法辅助激活,观察3组激活效果。结果:复苏的卵母细胞ICSI前培养3~4h后正常受精率、囊胚形成率明显高于培养1h、2h和5h实验组;A组激活率与B组相比,有明显差异(30.4%vs 6.7%,P<0.05);A组激活率和2PN2PB比例明显低于C组(30.4%vs 75.6%,P<0.05;21.4%vs 47.1%,P<0.05);A、C两组之间1PN2PB比例相比无统计学差异。结论:复苏的成熟卵母细胞ICSI前培养3~4 h后有助于卵母细胞结构的恢复,提高正常受精率和后期发育潜能。辅助激活在一定程度上可以挽救ICSI受精失败的卵母细胞;由于冻融损伤,复苏后ICSI受精失败的卵母细胞被辅助激活的能力明显下降。     

Loss of alternately spliced messenger RNA of the luteinizing hormone receptor and stability of the follicle-stimulating hormone receptor messenger RNA in granulosa cell tumors of the human ovary

OBJECTIVES: The expression of messenger RNA (mRNA) for the LH (LHR) and FSH receptors (FSHR) was examined in normal human corpora lutea and granulosa cell tumors. METHODS: Expression was examined by RT/PCR and DNA sequencing techniques. RESULTS: The full-length (FL) coding region and seven additional isoforms were identified for normal LHR mRNA. Isoform 1 had portions of exons II and III deleted, and isoform 2 had exon IX omitted. Isoform 3 also had portions of exons II and III deleted and all of exon IX deleted. Exons III through VI were missing in isoforms 4-7. Isoform 5 also had exon IX omitted, and isoform 6 also had part of exon XI missing. Isoform 7 also had exon IX and part of exon XI deleted. An aberrant migration pattern of the LHR mRNA isoforms was observed for granulosa cell tumors with FIGO Stage I-IV. Five tumor samples of Stage III-IV had many isoforms absent. Seven Stage I samples had aberrant migration patterns that depended on the size of the tumor. As the size of the tumor increased the aberrant migration pattern of the LHR mRNA isoforms was more pronounced and some isoforms were not detected. The FL and at least one additional isoform were identified for FSHR mRNA. Isoform 1 had regions of exons IV and V deleted. The FSHR mRNA isoforms had a similar migration pattern for the normal ovary and the granulosa cell tumors. CONCLUSIONS: Alternately spliced forms of mRNA for the LHR and FSHR exist for normal human ovary and granulosa cell tumors. The aberrant migration and missing LHR mRNA isoforms in granulosa cell tumors do not appear to result from general genomic instability associated with tumor progression. These findings are important to understand the role of alternate splicing in the regulation of LHR and FSHR expression in different pathological states.     

Recombinant follicle-stimulating hormone versus human menopausal gonadotropin in the late follicular phase during ovarian hyperstimulation for in vitro fertilization

OBJECTIVE: To study the effect of exogenous LH in the late follicular phase on ongoing pregnancies and at the different stages of IVF-ET (stimulation, fertilization, and implantation) in patients with low endogenous LH. DESIGN: Retrospective cohort study with modeling of the different phases of IVF-ET. SETTING: IVF center of the teaching hospital in Bordeaux, France. PATIENT(S): Women undergoing IVF and ICSI treatment. INTERVENTION(S): One group received recombinant FSH alone (FSH group) and the other received recombinant FSH and hMG in the late follicular phase (i.e., when the largest follicle reached 14 mm) (FSH/hMG group). MAIN OUTCOME MEASURE(S): Ongoing pregnancy, number of oocytes, and number of embryos.RESULT(S): The FSH/hMG group had a higher probability of having at least one oocyte (odds ratio [OR] = 2.75 [1.11-6.80]), of having at least one embryo after oocyte retrieval (OR = 2.84 [1.33-6.07]), and of ongoing pregnancy after ET (OR = 2.04 [0.83-5.01]), and globally had a higher probability of ongoing pregnancy (OR = 2.83 [1.19-6.71]). CONCLUSION(S): In ovarian hyperstimulation for IVF-ET, LH supplementation in the late follicular phase of women with low endogenous LH is beneficial for ongoing pregnancy by increasing the rate of success of all stages of the treatment.     

Ovulation induction in the new millennium: Recombinant follicle-stimulating hormone versus human menopausal gonadotropin

The renewed interest in luteinizing hormone (LH), together with limited and decreasing health resources, make essential the comparison of high-cost, recombinant follicle-stimulating hormone (rFSH) preparations (devoid of LH) and human menopausal gonadotropin (hMG) in terms of clinical efficacy. All published, randomized controlled trials (RCTs) comparing rFSH versus hMG under different protocols of stimulation were examined. Eight true RCTs were included in this meta-analysis, recruiting 2031 participants. Data for ongoing pregnancy/live birth rate, clinical pregnancy rate, miscarriage rate, multiple pregnancy rate and ovarian hyperstimulation syndrome (OHSS) were extracted, and odds ratios (ORs) and 95% confidence intervals (CIs) were calculated with the use of a fixed-effects model. Data for the meta-analysis were combined using RevMan software (using the Mantel–Haenszel method). Pooling the results of these RCTs showed no significant difference between rFSH and hMG regarding the different outcomes: ongoing pregnancy/live birth rate, OR 1.18 (95% CI 0.93–1.50); clinical pregnancy rate, OR 1.2 (95% CI 0.99–1.47), miscarriage rate, OR 1.2 (95% CI 0.70–2.16); multiple pregnancy rate, OR 1.35 (95% CI 0.96–1.90); incidence of moderate/severe OHSS, OR 1.79 (95% CI 0.74–4.33). However, there was significant reduction in the amount of gonadotropins in favor of hMG over rFSH. There was no significant heterogeneity of treatment effect across the trials. In conclusion, there is no clinically significant difference between hMG and rFSH in in vitro fertilization/intracytoplasmic sperm injection cycles. Decision-makers should establish their choice of one drug over the other based on the most up-to-date evidence available.     

Assessment of the calcium releasing machinery in oocytes that failed to fertilize after conventional ICSI and assisted oocyte activation

Research question

Can oocyte-related activation deficiencies be evaluated in oocytes that failed to fertilize after intracytoplasmic sperm injection (ICSI) combined with assisted oocyte activation (AOA)?

Outcome of conventional IVF and ICSI on sibling oocytes in the case of isolated teratozoospermia

Purpose

To reevaluate the effect of isolated teratozoospermia on IVF and determine if there was any therapeutic benefit to isolated teratozoospermia by ICSI, since there are no widely accepted criteria for the treatment technique about isolated teratozoospermia.

Methods

A total of 441 couples with >20 million and progressive motility >30 % sperm undergoing their first IVF/ICSI cycle were included in the study between 2008 and 2010, for whom at least 8 oocytes were retrived. Isolated teratozoospermia was diagnosed in 183 of the included couples, and the rest couples (normal sperm morphology) were studied as control. Sibling oocytes were randomized to be inseminated either by ICSI or IVF. Fertilization rate, embryo quality, pregnancy rate, implantation rate and spontaneous abortion rate were assessed.

Results

There was no difference in the percentage of eggs fertilized, implantation rate, pregnancy rate and spontaneous abortion rate between conventional IVF and ICSI regardless of the percentage of normal morphology. The day 3 embryonic morphology and rate of development were not different despite the insemination method and percentage of normal morphology.

Conclusion

Because isolated teratozoospermia did not influence the major indices of IVF and the unnecessary use of ICSI is time-consuming, costly and potential risks, couples with isolated teratozoospermia need not be subjected to ICSI.